ESR1 and breast carcinoma: For instance, treatment with trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, reactivated ERα expression in ERα-negative breast cancer cells through down-regulation of HDAC activity and consequential enrichment of the activating H3K9Ac mark on the ERα promoter [180].